Ingredient in pre-clinical treatment for retinal neovascular disease targets gene associated with acute myeloid leukaemia
An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that this compound, which targets an essential cancer gene, could kill leukaemia cells without harming non-leukemic blood cells.
The results, published today (19 December) in Nature Communications reveal a potential new treatment approach for an aggressive blood cancer with a poor prognosis.
Acute myeloid leukaemia (AML) is a form of blood cancer that affects people of all ages, often requiring months of intensive chemotherapy and prolonged hospital admissions. It develops in cells in the bone marrow crowding out the healthy cells, in turn leading to life-threatening infections and bleeding.
Mainstream AML treatments have remained unchanged for over 30 years, with the current treatment being chemotherapy, and the majority of people’s cancer cannot be cured. A subtype of AML, driven by rearrangements in the MLL gene has a particularly bad prognosis.
In a previous study, researchers at the Sanger Institute developed an approach, based on CRISPR gene editing technology, which helped them identify more than 400 genes as possible therapeutic targets for different subtypes of AML. One of the genes, SRPK1, was found to be essential for the growth of MLL-rearranged AML. SRPK1 is involved in a process called RNA splicing, which prepares RNA for translation into proteins, the molecules that conduct the majority of normal cellular processes, including growth and proliferation.
In a new study, Sanger Institute researchers and their collaborators set out to work out how inhibition of SRPK1 can kill AML cells and whether it has therapeutic potential in this disease. They first showed that genetic disruption of SRPK1 stopped the growth of MLL-rearranged AML cells and then went on to study the compound SPHINX31, an inhibitor of SRPK1, which was being used to develop an eye drop treatment for retinal neovascular disease – the growth of new blood vessels on the retinal surface that bleed spontaneously and cause vision loss.
The team found that the compound strongly inhibited the growth of several MLL-rearranged AML cell lines, but did not inhibit the growth of normal blood stem cells. They then transplanted patient-derived human AML cells into immunocompromised mice and treated them with the compound. Strikingly, the growth of AML cells was strongly inhibited and the mice did not show any noticeable side effects.
“We have discovered that inhibiting a key gene with a compound being developed for an eye condition can stop the growth of an aggressive form of acute myeloid leukaemia without harming healthy cells. This shows promise as a potential approach for treating this aggressive leukaemia in humans.”
Dr George Vassiliou, joint leader of the research from the Wellcome Sanger Institute and the Wellcome-MRC Cambridge Stem Cell Institute
SRPK1 controls the splicing* of RNA in the production of new proteins. An example of a gene that is affected when SRPK1 is blocked is BRD4, a well-known gene that maintains AML. Inhibiting SRPK1 causes the main form of BRD4 to switch to another form, a change that is detrimental to AML growth.
“Our study describes a novel mechanism required for leukaemia cell survival and highlights the therapeutic potential of SRPK1 inhibition in an aggressive type of AML. Targeting this mechanism may be effective in other cancers where BRD4 and SRPK1 play a role, such as metastatic breast cancer.”
Dr Konstantinos Tzelepis, joint lead author from the Wellcome Sanger Institute and University of Cambridge
“When Dr Vassiliou told me that SRPK1 was required for the survival of a form of AML, I immediately wanted to work with him to find out if our inhibitors could actually stop the leukaemia cells growing. The fact that the compound worked so effectively bodes well for its potential development as a new therapy for leukaemia. It will take some time, but there is real promise for a new treatment on the horizon for patients with this aggressive cancer.”
Professor David Bates, from the University of Nottingham and co-founder of biotech company Exonate, which develops eye drops for retinal diseases
Learn more: From eye drops to potential leukaemia treatment
The Latest on: Acute myeloid leukaemia
via Google News
The Latest on: Acute myeloid leukaemia
- Late Effects of Therapy Plague Many Patients Who Survived AML as Youths, Young Adultson November 22, 2020 at 4:32 pm
Most patients who are diagnosed with acute myeloid leukemia are in middle or old age. The relatively small number who are diagnosed earlier in life can be subject to long-term health risks due to ...
- MedWatch Today: Woman Battles Leukemia During Pregnancyon November 22, 2020 at 1:48 pm
Pregnancy can be an exciting and stressful time, both physically and mentally. But imagine receiving a cancer diagnosis while being pregnant. That’s what happened to one local woman. Jiovana ...
- Glycostem initiates phase I/IIa (pivotal) trial to evaluate the safety and efficacy of oNKord® in patients with Acute Myeloid Leukemia (AML)on November 20, 2020 at 4:24 am
Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, today announced the opening of a phase I/IIa trial for ...
- 2020 Market Study on the Acute Myeloid Leukemia Market in Europe - ResearchAndMarkets.comon November 20, 2020 at 2:47 am
The "Europe Acute Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights into the Acute ...
- Novel Assay Identifies Mutations, Fusions, Exon Skipping in Myeloid and Lymphoid Malignancieson November 19, 2020 at 5:31 pm
In an interview with Targeted Oncology during the Association for Molecular Pathology 2020 Annual Meeting, Rachel Sparks, MD, discussed the findings observed in hematologic malignancies with the use ...
- Global Acute Myeloid Leukemia Therapeutics Market Could Exceed $3.5 Billion By 2027on November 19, 2020 at 8:09 am
PALM BEACH, Fla., /PRNewswire/ -- According to the American Cancer Society, the number of new acute myeloid leukemia cases is estimated to continue to grow in the U.S. due to a number of factors. The ...
- Epigenetic silencing of miR-564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.on November 18, 2020 at 10:13 pm
The AML1-ETO oncoprotein, which results from t(8;21) translocation, is considered an initial event of t(8;21) acute myeloid leukemia (AML). However, the precise mechanisms of the oncogenic activity of ...
- The Possibilities in AML With the FDA Approval of Azacitidine and Venetoclaxon November 15, 2020 at 4:00 pm
Brain A. Jonas, MD, discusses the future of treatment for older patients with acute myeloid leukemia, now that the FDA has granted approval to azacitidine plus venetoclax for patients aged 75 years or ...
- Young AML survivors face long-term health troubleon November 13, 2020 at 10:00 am
Young survivors of acute myeloid leukemia, notably non-white patients and those in deprived neighborhoods, have a high risk of long-term health issues.
- Uncovering TP53 Mutations in MDS, AML Requires NGSon November 12, 2020 at 7:36 am
TP53-targeted treatment options represent an unmet need for patients with myelodysplastic syndromes and acute myeloid leukemia.
via Bing News